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Introduction
With advancements in the management of coronary artery 
disease, arrhythmias, and congenital heart disease, in addi-
tion to the development of predisposing comorbidities, more 
and more patients are surviving heart failure (HF). There are 
an estimated 825,000 new diagnoses of HF in a year, and 
5.1 million adult Americans suffer from the disease.1 Though 
there has been a significant reduction in mortality from HF 
because of beta blockers, ACE-inhibitors, and automatic 
implantable cardioverter defibrillators,2 many patients still 
present with cardiogenic shock. This remains a challenge for 
the practitioner and is associated with significant morbidity 
and mortality.
Over the last several decades, temporary mechanical cir-
culatory support (MCS) devices have been an effective means 
of acute support in patients with cardiogenic shock or in the 
setting of high-risk interventions such as revascularization or 
ablation.3–6 There has been significant technologic development 
in the field of circulatory support, with options including intra-
aortic balloon pump (IABP), extracorporeal membrane oxygen-
ation (ECMO), CentriMag® pump, and several percutaneous 
ventricular assist devices (pVADs), such as the  TandemHeart® 
and Impella® systems. When the method of temporary circula-
tory support is chosen and applied to the appropriate setting, 
these devices can effectively aid in bridging patients to hemo-
dynamic stabilization or more definitive management. This 
review focuses on describing the hemodynamic goals, clinical 
indications, and various device options for current generation 
temporary MCS devices, in addition to highlighting ongoing 
research and future directions in the field.
Goals of Temporary MCS
The primary hemodynamic goals of temporary MCS are to 
decrease preload, decrease afterload, and augment cardiac 
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output. The end goal is to provide adequate organ perfusion 
and oxygen delivery, which can bridge patients to recovery 
or a more durable device, as well as support them through a 
high-risk procedure (Table 1). Temporary MCS can be used 
to mechanically unload the left ventricle and right ventricle 
or provide biventricular support, with or without concomitant 
ECMO to replace pulmonary gas exchange.
As MCS devices continue to develop, they must be prac-
tical in the real world of HF management. In addition to 
providing optimization of hemodynamics, these devices must 
have a desirable risk/benefit ratio with demonstrable safety 
and efficacy. Additionally, they should be feasible and eco-
nomical, with relative ease of insertion and availability.
Circulatory Support options
Intra-aortic balloon pump. The IABP was first devel-
oped on the hemodynamic basis of diastolic augmentation 
and counterpulsation. Kantrowitz and colleagues described 
the first published experience with an intra-aortic circulatory 
assist device in a case series of patients with cardiogenic shock 
in 1968.3 A few years later, Scheidt and colleagues demon-
strated improvement in hemodynamics, an increase in car-
diac output by 500 mL/minute, and a decrease in lactate in 
80 patients with cardiogenic shock.7
The IABP is placed via arterial access, most commonly 
femoral, into the descending aorta (Ao). During diastole, the 
balloon inflates, providing an augmented diastolic pressure and 
coronary perfusion. During systole, the balloon deflates rap-
idly, creating a temporary vacuum that reduces aortic pressure 
(ie, afterload) and enhances left ventricular (LV) unloading. 
Overall effects of the IABP are a modest increase in cardiac 
output and stroke volume; decrease in LV preload, LV end-
diastolic pressure, LV wall stress, and afterload; and improved 
coronary perfusion and systemic blood pressure (Table 2).
IABP placement initially developed as a surgical tech-
nique; however, it is now placed by interventional cardiologists 
in the cardiac catheterization laboratory and can be emergently 
placed at the bedside in an unstable patient. It is considered a 
safe and quick procedure in experienced hands. An alternative 
to the femoral approach, which requires patients to be immo-
bilized, is axillary placement, which allows patients to be out 
of bed and is beneficial for prolonged use, such as in the bridge 
to transplant (BTT) setting.8
Over the years, indications for IABP have broadened. 
Cardiogenic shock secondary to acute myocardial infarction 
(AMI) remains the most common indication. Additional 
indications include postcardiotomy shock (PCS), refractory 
HF, optimization, and bridge prior to cardiac surgery and 
during high-risk cardiac procedures. IABP is contraindicated 
in patients with aortic insufficiency and aortic dissection. 
 Relative contraindications also include sepsis and peripheral 
vascular disease. Complications include bleeding,  vascular 
injury, thrombocytopenia, and infection (Table 3). Rates of 
complication have been high in the past, but more recent large 
studies suggest an overall angio-ischemic complication rate of 
8–18%, with major limb ischemia in less than 1% of patients.9,10 
The newer fiber optic IABP by Maquet (Fairfield, NJ, USA) 
uses a smaller (7 Fr) catheter that may decrease  vascular com-
plications; however, use is not yet widespread.
extracorporeal membrane oxygenation. ECMO 
involves use of a centrifugal pump to drive blood from the 
patient through an externalized membrane oxygenator system 
for carbon dioxide and oxygen exchange before returning to 
the patient’s arterial system. Cannulation sites include femo-
ral artery and vein (venoarterial, VA) or internal jugular vein/
right atrium (RA) and common femoral vein (venovenous, 
VV) (Fig. 1). In addition to assisting in gas exchange, VA 
ECMO can augment cardiac output.
Advantages of ECMO include the ability to oxygenate 
blood in hypoxemic states and unload both the right and left ven-
tricles. Peripheral ECMO cannulas can be placed at the bedside 
Table 1. indications for temporary mechanical circulatory support.
Cardiogenic shock due to:
•   acute myocardial infarction and related mechanical complications
•  acute decompensated heart failure
•  acute myocarditis
•  Post-cardiotomy shock
•   acute rejection post-cardiac transplant with hemodynamic 
compromise
High-risk interventions
•  Percutaneous coronary intervention
•  Ventricular tachycardia ablation
bridge to lVAD or transplant
Right ventricular failure
Abbreviation: lVad, left ventricular assist device.
Table 2. hemodynamic effects of mechanical circulatory support 
devices.
IAbP eCMO TAnDeM-
HeART
IMPellA
afterload reduced increased increased neutral
lV stroke 
volume
slight  
increase
reduced reduced reduced
Coronary 
perfusion
slight  
increase
Unknown Unknown Unknown
lV preload slightly  
reduced
reduced reduced slightly 
reduced
PCWP slightly  
reduced
reduced reduced slightly 
reduced
 Peripheral 
tissue 
perfusion
No significant 
increase
improved improved improved
note: adapted from Werdan K, gielen s, ebelt h and hochman Js, 
“Mechanical circulatory support in cardiogenic shock,” European Heart 
Journal (2014) 35, 156–67, by permission from oxford University Press and 
european society of Cardiology.
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in an emergency using a cut-down technique. The aim of ECMO 
is to provide acute, temporary support or serve as a bridge to 
more durable therapy. Complications include risk of limb isch-
emia, bleeding, and hemolysis. The American Heart Association 
Guidelines for Cardiopulmonary Resuscitation state that ECMO 
is reasonable to perform and its benefit outweighs risk in the set-
ting of cardiac arrest or shock because of a potentially reversible 
condition, such as myocarditis.11 Despite advancements in device 
technologies described below, ECMO has been shown to have 
comparable clinical outcomes when compared with percutane-
ously inserted ventricular assist devices (VADs).12
CentriMag. The CentriMag® (Thoratec Corporation) is 
an extracorporeal, surgically implanted centrifugal pump that 
can provide up to 10 L/minute of blood flow. It is a third-
 generation continuous flow pump with a magnetically sus-
pended rotor, which has minimal friction, thus reducing shear 
force on red blood cells with less hemolysis. The CentriMag 
system is currently Food and Drug Administration (FDA) 
approved for LV support up to six hours. It is approved for 
support when there is acute right ventricular (RV) failure for 
up to 30 days (Humanitarian Use Device), and longer term 
use is currently investigational only.13 The CentriMag system 
Table 3. Contraindications and complications associated with temporary circulatory support.
DeVICe COnTRAInDICATIOnS COMPlICATIOnS
all devices severe peripheral vascular disease
irreversible neurologic disease
sepsis*
Bleeding
Vascular injury
infection
neurologic injury
iaBP Moderate to severe aortic insufficiency
aortic dissection
abdominal aortic aneurysm
Contraindication to anticoagulation*
thrombocytopenia
thrombosis
Obstruction of arterial flow due to malposition
aortic rupture or dissection
air or plaque embolism
eCMo Mechanically ventilated .7 days
Contraindication to anticoagulation
thrombosis of circuit
Upper body hypoxia due to incomplete retrograde oxygenation
lV dilatation
systemic gas embolism
CentriMag Contraindication to anticoagulation thromboembolic events
air embolism
tandemheart Ventricular septal defect
Moderate to severe aortic insufficiency
Contraindication to anticoagulation
Cannula migration
tamponade due to perforation
thromboembolism
air embolism during cannula insertion
inter-atrial shunt development
impella lV thrombus
Moderate to severe aortic stenosis
Moderate to severe aortic insufficiency
Mechanical aortic valve
recent tia or stroke
aortic abnormalities
Contraindication to anticoagulation
hemolysis
Pump migration
aortic valve injury
Aortic insufficiency
tamponade due to lV perforation
Ventricular arrhythmia
note: *relative contraindication.
Abbreviations: eCMo, extracorporeal Membrane oxygenation; iaBP, intra-aortic balloon pump; lV, left ventricular; tia, transient ischemic attack.
VA-ECMO VV-ECMO
Femoral artery Internal jugular vein
Returning oxygenated
blood
De-oxygenated blood
figure 1. a schematic representation of peripheral Va (Va eCMo) and VV-eCMo. From Cove Me, Maclaren g. Clinical review: MCs for cardiogenic shock 
complicating acute myocardial infarction. Crit Care. 2010;14:235; originally published by BioMed Central with permission from MaQUet gmbh & Co. Kg.
Gilotra and Stevens
78 CliniCal MediCine insights: Cardiology 2014:8(s1)
can provide left and/or RV support with placement of outflow 
(22 Fr) and inflow (32 Fr) cannulas in the left atrium (LA)/Ao 
or RA/pulmonary artery (PA), respectively (Fig. 2). The pump 
can also be used peripherally in an ECMO circuit.
In a multicenter study of 38 patients supported by the 
CentriMag for various indications and a combination of left, 
right, or biventricular support, the device provided effec-
tive short-term support with a 47% 30-day mortality rate 
and low complication rate. The most common complications 
were infection, bleeding, and thromboembolic neurologic 
events (though three of four of these events were question-
ably related to device).14 Contraindications include bleeding 
that precludes the use of heparin for anticoagulation during 
device support.
Percutaneous ventricular assist devices. TandemHeart. 
The TandemHeart System® (CardiacAssist, Inc.) is a LA to 
femoral artery bypass system (Fig. 1). This pVAD consists of a 
21F venous transseptal inflow cannula, a continuous flow cen-
trifugal blood pump with an electromagnetically suspended and 
driven impeller, and an arterial perfusion catheter.  Oxygenated 
blood is withdrawn from the LA; which is accessed by standard 
transseptal technique involving placement of the 21F cannula, 
which contains 14 side holes and a large end hole; and pumped 
to the systemic circulation via a 17F femoral artery catheter, 
thereby bypassing the left heart. Patients should undergo an 
aortogram with runoff to assess the degree of peripheral vas-
cular disease prior to catheter insertion. RV support can be 
achieved by placing the inflow cannula in the RA and outflow 
cannula in the PA. The TandemHeart pump can also be surgi-
cally implanted similar to the CentriMag described above to 
support either or both ventricles.
Thiele and colleagues first described the use of the 
TandemHeart in 18 patients with AMI complicated by cardio-
genic shock. The device was implanted for a mean of 4 ± 3 days, 
and the use resulted in a significant improvement in cardiac 
index (from 1.7 L/minute/m2 to 2.4 L/minute/m2), increase in 
mean arterial pressure (from 63 to 80 mmHg), and decrease 
in filling pressures. In all, 30-day mortality was reported to be 
44%.15 The TandemHeart gained FDA approval in 2003.
Hemodynamically, the TandemHeart significantly reduces 
preload and augments cardiac output, with the ability to pump 
up to 4 L/minute. It has been shown to have superior effects 
on hemodynamics than the IABP.16,17 Of note, the device is 
preload dependent, with an ideal pulmonary capillary wedge 
pressure maintained between 18 and 20 mmHg.18 Once the 
pump is started, pulmonary capillary wedge pressure should 
be monitored to ensure adequate filling and pump flow. Addi-
tionally, there is high risk of thromboembolism necessitating 
the need for systemic anticoagulation with heparin.
Contraindications include ventricular septal defect (which 
would then cause right to left shunting and hypoxemia), aortic 
insufficiency, severe peripheral vascular disease, and inabil-
ity to be on systemic anticoagulation. The  TandemHeart has 
several possible complications, and percutaneous placement 
requires an experienced operator familiar with the technique of 
transseptal puncture. Complications include distal limb isch-
emia, bleeding, infection, tamponade because of perforation at 
the time of transseptal puncture, thromboembolism, and air 
embolism at the time of insertion of large cannulae.19,20
Impella system. The Impella® 2.5 system (Abiomed) is a 
9-Fr catheter-mounted, 2.5 L/minute, impeller-driven, axial-
flow pump that is placed in a retrograde fashion across the 
aortic valve via a cardiac catheterization procedure (Fig. 3). 
The pigtail-tipped catheter sits in the left ventricle and pumps 
blood out to the ascending Ao. It received FDA approval in 
2008. The 5.0 L/minute Impella® 5.0 or Impella® LD (both 
FDA approved in 2009) is larger and requires surgical cut 
down of the femoral or axillary artery or an open heart proce-
dure, respectively. These devices can be inserted for short-term 
support, typically up to five days.19
The Impella requires systemic anticoagulation. Complica-
tions include bleeding, vascular injury, infection, and hemoly-
sis. Another concern is pump migration if the catheter becomes 
dislodged in any way. Contraindications include LV thrombus, 
moderate aortic stenosis or aortic insufficiency, recent stroke or 
TIA, and structural abnormalities of the Ao.19
Total artificial heart (TAH). The TAH is a complete 
cardiac replacement strategy, first successfully implanted 
in 1982.21 The only current FDA-approved device in the 
United States as a BTT is the SynCardia temporary TAH 
(SynCardia Systems, Inc). It may be used for destination 
therapy under the Humanitarian Use Device designation 
in the United States. It consists of a 70-cc pneumatically 
driven pump with tilting disk valves and short outflow grafts 
replacing both ventricles, the proximal Ao and PA, and the 
four valves. A left ventricle is connected to the LA via a left 
atrial inflow connector and to the Ao via an outflow cannula. 
A right ventricle is connected to the RA via a right atrial 
inflow connector and to the PA via an outflow cannula. The 
ventricular drivelines tunnel through the chest wall and con-
nect to the external  console. Size  requirements include a body 
surface area $1.7 m2 and chest AP diameter $10 cm.22,23 
Additionally, there is a smaller, 50 cc, TAH in development 
for patients with a body surface area of 1.2–1.79 m2, which 
may help overcome the primary size contraindication for 
figure 2. (A) a CentriMag blood pump and (b) a schematic diagram of 
possible CentriMag cannulation sites: la and ao for lV support versus 
ra and Pa for rV support. image courtesy of thoratec Corporation.
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placement. In a single-center experience of 101 patients using 
SynCardia TAH as a BTT, mean support time was 87 days 
with 68.3% survival rate. Major adverse events were stroke 
(7.9%) and reoperation because of hemorrhage (24.7%).23 The 
Freedom® portable driver, a wearable system that runs the 
SynCardia TAH and allows discharge to home, was recently 
FDA approved on June 26, 2014.
Clinical Indications for Temporary MCS
Cardiogenic shock because of AMI. Ischemic heart 
disease continues to be the most common cause of HF, and 
cardiogenic shock is still a frequent complication of AMI. In 
fact, most early studies of cardiogenic shock were performed 
in patients with AMI, and the majority of data regarding the 
use of MCS are still in this setting.
With its favorable hemodynamic effects of decreased 
afterload and increased coronary perfusion, it is not surpris-
ing that the American College of Cardiology and American 
Heart Association (ACC/AHA) initially deemed that there 
was enough evidence that IABP placement should be per-
formed when managing cardiogenic shock in the setting of 
ST-elevation myocardial infarction (STEMI). However, 
much of these data were based on registries, with poor level of 
evidence, and the newest guidelines have actually changed the 
recommendation for IABP as well as other LV assist devices 
to reasonable to perform rather than should be performed.24 In 
fact, recent data suggest that IABP may have less of a role in 
acute management of STEMI with cardiogenic shock than 
was previously thought.25
Sjauw and colleagues published a recent two-part meta-
analysis of IABP utilization in STEMI.25 The first included 
seven randomized trials encompassing a total of 1009 STEMI 
patients. In this population, IABP did not show any benefit 
for 30-day survival. The second looked specifically at studies 
of STEMI patients with cardiogenic shock and IABP. They 
divided the studies based on treatment: thrombolysis versus 
primary percutaneous coronary intervention (PCI). Though 
patients receiving thrombolytics and IABP placement had an 
18% decrease in 30-day mortality (P , 0.0001) compared to 
those without the IABP, patients initially revascularized with 
PCI rather than thrombolytics had a 6% increase in 30-day 
mortality (P , 0.0008).25 It should be noted, however, that 
the nine studies in this meta-analysis were all cohort stud-
ies, as there had not been any randomized controlled trials 
of IABP use in AMI complicated by shock. In a Cochrane 
Database of Systematic Reviews’ meta-analysis of six eligible 
and two ongoing studies comparing IABP to either standard 
treatment or to percutaneous left assist devices in 190 patients 
with AMI and cardiogenic shock, the all-cause 30-day mor-
tality hazard ratio was 1.04 (95% CI, 0.62–1.73).26
In an attempt to address the lack of data on utility of 
IABP in shock with AMI, the IABP-SHOCK II investigation 
randomized 600 patients expected to undergo early revascu-
larization (PCI or coronary artery bypass grafting) in a pro-
spective, open-label, multicenter trial to IABP or no IABP.27 
The primary endpoint of 30-day mortality was met in 39.7% 
of patients in the IABP group and 41.3% of patients with-
out IABP (P = 0.69). No significant differences in  secondary 
endpoints or rates of major bleeding, peripheral ischemic 
complications, sepsis, or stroke were found. There was a non-
significant trend toward higher rate of VAD placement in the 
group without IABP. Also, 10% of patients randomized to the 
control group underwent IABP placement; most of them were 
protocol violation. Follow-up data at 12 months did not show 
any benefit in the IABP-treated group.28 These data, together 
with the meta-analysis by Sjauw et al, suggest that in patients 
figure 3. an illustration of options for MCs: (A) iaBP, (b) tandemheart, and (C) impella. From desai nr, Bhatt dl. evaluating percutaneous support for 
cardiogenic shock: data shock and sticker shock. Eur Heart J. 2009;30:2073–2075, by permission from oxford University Press and european society of 
Cardiology.
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who are successfully revascularized with primary PCI (95.8% 
of patients in IABP-SHOCK II), IABP may not provide 
additional benefit.
In a head-to-head randomized comparison between the 
TandemHeart and IABP in patients undergoing primary 
PCI, hemodynamics were significantly improved in the pVAD 
group; however, there were more complications with similar 
30-day mortality rates (though the study was not powered for 
mortality). Of note, in this study, a high percentage of patients 
received thrombolytics and there was no screening aortogram/
aortoiliac runoff prior to placement of either device.16 Another 
study in patients with mostly myocardial infarction (MI)-
related cardiogenic shock confirmed the hemodynamic benefit 
of the TandemHeart, though a lack of survival benefit, when 
compared with IABP.17
Given the high mortality in patients with STEMI com-
plicated by shock, continued attention has been focused at 
unloading the left ventricle and improving hemodynamics 
and survival in this patient population. With mixed data from 
IABP trials and the risks associated with the placement of the 
TandemHeart, focus was shifted to the Impella 2.5. The use of 
the Impella 2.5 has also improved outcomes in patients with 
shock in the setting of acute ischemia, especially when initi-
ated early, ie, prior to revascularization.29 The EUROSHOCK 
Registry was a retrospective study of 120 patients with car-
diogenic shock because of AMI undergoing implantation of 
Impella 2.5. There was a decrease in lactate levels at 48 hours 
suggesting improved organ perfusion, but 30-day mortal-
ity remained high at 64.2%.4 Patients who received Impella 
2.5 support prior to primary PCI in the setting of AMI and 
cardiogenic shock, rather than after PCI, fared better.30 The 
Impella 2.5 has also shown beneficial LV remodeling and 
unloading in anterior STEMI patients without cardiogenic 
shock.31
When compared with the IABP, the Impella 2.5 more 
substantially improves hemodynamics though no randomized 
trials have been powered for a primary endpoint of mortal-
ity.32 The most recent RE-COVER II trial, which also aimed 
to compare the Impella 2.5 with the IABP, was terminated 
because of incomplete enrollment.33
Cardiogenic shock complicating AMI remains the lead-
ing cause for need of LV support. Though pVADs have shown 
an improvement in hemodynamics, further larger, randomized 
studies are necessary to demonstrate a clear mortality benefit.
High-risk PCI in the setting of cardiomyopathy. pVAD 
has an additional role in ischemic heart disease as an adjunct to 
high-risk PCI in the setting of severe LV dysfunction and/or 
cardiogenic shock. ECMO-assisted primary PCI in the set-
ting of cardiogenic shock complicating AMI has been shown 
to improve survival.34,35 The IABP has been used for years 
to provide mechanical support in high-risk  interventional 
settings; however, as outlined above, it provides only  modest 
improvement in hemodynamics and cannot provide actual 
 circulatory support.
Both the TandemHeart and Impella 2.5 can be used 
at the time of high-risk PCI, with periprocedural insertion 
and removal in the cardiac catheterization lab. Aragon and 
colleagues published their early results using the Tandem-
Heart in a small (n = 8) group of patients undergoing high-
risk PCI.36 All patients had low LV systolic function and 
multi-vessel disease, with three patients having left main 
disease. They described procedural success and ability to 
obtain short-term hemodynamic stability in all patients. Two 
small studies, including the PROTECT I study, have dem-
onstrated feasibility and efficacy of the Impella 2.5 during 
high-risk PCI in similar patient cohorts.37,38 A retrospective 
analysis of the Europella Registry (144 patients) also dem-
onstrated safety and feasibility, with a 5.5% 30-day mortal-
ity rate.39 Both the TandemHeart and the Impella 2.5 have 
similar procedural, in-hospital and long-term outcomes in 
their prospective high-risk PCI cohorts, although there are 
no randomized studies comparing these two devices in this 
clinical situation.40
The subsequent and larger prospective, randomized con-
trolled trial, PROTECT II, compared periprocedural support 
using the Impella 2.5 versus IABP in 452 patients with systolic 
HF (mean ejection fraction [EF] 24%) undergoing high-risk 
PCI. After 69% of expected enrollment, the trial was stopped 
early because of futility. Though support with the Impella 2.5 
provided a superior hemodynamic profile, there was no sig-
nificant difference in the primary endpoint of 30-day major 
adverse cardiovascular events (MACE). However, at 90 days, 
the non-significant difference between the two groups’ 30-day 
MACE rate did trend toward a wider difference (40.6% versus 
49.3%, P = 0.066) in the intention-to-treat analysis and a sig-
nificant difference in the per protocol analysis (40.0% versus 
51.0%, P = 0.023, yielding a relative risk reduction of 22%).5
Ventricular tachycardia. Ventricular tachycardia (VT) 
frequently accompanies end-stage cardiomyopathy and can 
lead to significant hemodynamic instability. Medical man-
agement and defibrillator therapy alone may not be enough 
to control VT; therefore, catheter ablation strategies are now 
more frequently pursued, especially when involving infarct-
related scar. However, induction of VT during activation 
mapping can lead to further instability, and in this setting, 
substrate- and pace-mapping techniques can alternatively 
be used but may not be effective in eliminating VT. Though 
IABP support is indicated for decompensation in the setting 
of refractory arrhythmia, its optimal use can be challenging 
during VT. Percutaneous support devices can assist during 
arrhythmia induction by lending hemodynamic stability.
Friedman and colleagues first described the successful 
use of the TandemHeart in a single patient undergoing endo-
cardial and epicardial VT ablation.6 This has been shown to 
allow identification and ablation of a greater number of VT 
foci.41 In this retrospective study, there was no difference in 
long-term outcomes between the TandemHeart-supported 
group and the substrate-mapped strategy group; however, 
Temporary mechanical support
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the pVAD group may have been a sicker cohort to begin with 
since patients were not randomized.
The Impella 2.5 has also been successfully used dur-
ing unstable VT ablation as described in case reports and a 
few small studies.42–44 Miller and colleagues retrospectively 
showed that the use of the Impella 2.5 allowed longer time 
in induced VT (66.7 versus 27.5 minutes; P = 0.03) as well as 
fewer early terminations of VT for hemodynamic instability 
(1.0 versus 4.0; P = 0.001). Hemodynamically, they demon-
strated that there was no difference in cerebral deoxygenation 
as monitored by cerebral oximetry, hypotension, or markers 
of perfusion.43 In a subsequent non-randomized, prospec-
tive study of scar-mediated VT in patients with severe LV 
dysfunction, the same group conducted the percutaneous 
hemodynamic support with Impella 2.5 during scar-related 
ventricular tachycardia ablation (PERMIT1) study. They 
demonstrated that during fast simulated VT, more favorable 
hemodynamics were achieved with pVAD support. Interest-
ingly, they employed cerebral oximetry with a threshold of 
55% to guide duration of VT mapping. Cerebral desaturation 
(#55%) occurred in 53% of patients tested without Impella 
2.5 support but in only 5% of patients with full support.44 
These studies suggest that the use of pVAD support during 
unstable VT ablation will allow a more complete, safe, and 
successful procedure.
bridging refractory HF. Temporary MCS may be neces-
sary to decide on more definitive therapy (bridge to decision, 
BTD) or to optimize patients prior to LVAD or transplant 
(bridge to bridge or BTT). Though patients requiring mechani-
cal support do worse early on, if they survive to transplant, they 
do as well as their counterparts who did not require mechani-
cal support.45 Until recently, the only percutaneous option in 
this setting was IABP or ECMO; however,  prolonged use is 
associated with complications (see Intra-Aortic Balloon Pump 
and Extracorporeal Membrane Oxygenation sections).46,47 
Although more durable mechanical support may more effec-
tively bridge a patient to definitive therapy, surgical placement 
may be too risky in a patient with acute cardiogenic shock, and 
percutaneously placed VADs may be more practical in this 
situation.48,49
pVADs have been utilized in a variety of clinical situa-
tions involving patients who may eventually require more per-
manent support or heart transplantation. The TandemHeart 
was first used as a BTT in 2005 for six days until successful 
heart transplantation.50 Gregoric and colleagues described 
the use of the TandemHeart as a bridge to a long-term axial-
flow LVAD in nine patients with acute refractory cardio-
genic shock.51 Brinkman et al studied the TandemHeart in 
11 patients as BTT or potential recovery and an additional 
11 patients with questionable neurologic status or multiorgan 
failure as BTD. In all, 4 of the latter 11 patients survived: 
1 recovered, 1 received an LVAD, 1 received an LVAD and 
then transplant, and 1 underwent transplantation. The other 
seven died after a mean of three days of support. The authors 
stated that pVAD insertion allowed time for more complete 
evaluation before proceeding with long-term therapy, which 
is key to the success of the more durable therapies. Of the 
BTT population, 1 died because of infectious complications, 
10 had successful TandemHeart explants with 3 subsequently 
receiving a durable LVAD (2 eventually were transplanted), 
5 received a heart transplant, and 2 were recovered.52  Bruckner 
and colleagues examined the hemodynamic effects of the 
 TandemHeart in five patients with refractory cardiogenic 
shock.53 They demonstrated an improvement in cardiac index, 
mean arterial pressure, mixed venous oxygen saturation, and 
urine output from baseline (Table 4). The device decreased 
central venous pressure; however, it did not have a significant 
effect on pulmonary capillary wedge pressure or renal func-
tion. After an average duration of 7.6 ± 3.2 days support, all 
patients were successfully bridged to transplant. The Impella 
has also been used as a BTT. Garatti and colleagues described 
use of the Impella LD or LP in six patients as BTT, two of 
whom required VAD support and died.54 The authors con-
cluded that the Impella device may be utilized to provide 
support until long-term device placement (as a double bridge) 
rather than directly to transplant. In summary, patients with a 
dramatic hemodynamic improvement with pVAD placement 
may benefit from urgent transplant listing, whereas those who 
do not demonstrate such clinical improvement may benefit 
from first being bridged with more durable support.
One of the most common nonischemic causes of acute 
HF that may require mechanical support as a bridge to recov-
ery (BTR) is acute myocarditis. Though patients with acute, 
fulminant myocarditis have been shown to have better long-
term outcomes than those with non-fulminant myocarditis, 
they often initially require temporary support if inotropes 
and IABP have failed.55,56 Several case reports and series 
have demonstrated the utility of pVAD insertion for this 
 purpose.57–59 Chandra and colleagues described the first three 
patients with acute myocarditis who successfully recovered on 
Table 4. hemodynamic values before and after tandemheart 
placement.
befORe AfTeR
Cardiac index, l/(min*min2) 1.9 ± 0.3 3.5 ± 0.8
Pressors used (n) 2.4 ± 1.1 1.0 ± 0.7
Mean arterial pressure (mmhg) 69 ± 12.5 91 ± 4.3
Pulmonary capillary wedge  
pressure (mmhg)
30.4 ± 8.6 21.8 ± 4.3
Mixed venous oxygen saturation (%) 45.4 ± 14.3 71.4 ± 7.5
Central venous pressure (mmhg) 21.2 ± 7.4 12.8 ± 5.9
Urine output (ml/24 hr) 1,861 ± 988 4,314 ± 1.34
Blood urea nitrogen (mg/dl) 46.2 ± 44.2 44.6 ± 33.1
Creatinine (mg/dl) 1.8 ± 0.7 1.6 ± 0.5
notes: Values are expressed as mean ± sd. adapted with permission from 
Bruckner et al.53 Copyright 2008 by the texas heart institute. 
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the TandemHeart, with a mean duration of support of five 
days.58 Khalife and Kar similarly described two patients with 
acute fulminant myocarditis who were successfully toward 
BTR using the TandemHeart.59 When deciding on the mode 
of support (temporary versus more permanent) in patients 
with acute myocarditis, it is important to identify those who 
may require more durable support. Though a pVAD can be 
used as a bridge to a bridge (ie, to a durable LVAD), some 
patients, such as those with giant cell myocarditis, may benefit 
from more durable, or even biventricular, support from the 
outset as recovery times are longer and may entail waiting for 
heart transplantation.56
Additionally, pVADs can be used in patients presenting 
with allograft rejection. IABP and ECMO are often used 
in this situation to stabilize patients while they are being 
treated for rejection; however, they may require longer-term 
support for recovery. Rajagopal and colleagues describe 
a patient who had biventricular pVAD support using the 
Impella 2.5 for the LV and the TandemHeart for refractory 
RV failure.60 Both devices were successfully weaned and 
removed after adequate treatment of the patient’s cardiac 
allograft rejection.
Optimal timing of device implantation in these patients 
is imperative. The Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) has defined 
seven clinical profiles of patients being considered for VAD 
therapy (Table 5).61 INTERMACS profile 1 (crash and burn) 
and profile 2 (sliding on inotropes) patients should be con-
sidered for VAD, either temporarily or permanently, very 
quickly, although clinical outcomes for INTERMACS pro-
file 1 patients receiving a surgically implanted, durable VAD 
are worse than for those in higher INTERMACS profiles.62 
Additionally, pre-implantation risk factors for mortality after 
durable LVAD implantation have been identified in several 
studies.63,64 Most formalized risk models, however, are for 
transplant candidacy and originate from ambulatory data. 
These data are less applicable to the inpatient population 
requiring pVADs; and therefore, patient identification should 
be based on INTERMACS profile and clinical judgment. 
Additionally, a feasible exit strategy should be identified prior 
to implantation.
Postcardiotomy shock. PCS is one of the leading causes 
of death after cardiac surgery, usually because of multiorgan 
failure. Approximately 0.2–6% of patients undergoing  cardiac 
surgery develop PCS with survival to discharge ranging from 
19.5% to 52.4%.65 IABP and inotropic therapy alone may 
not suffice in patients who develop PCS when weaning off 
 cardiopulmonary bypass (CPB). The use of ECMO, especially 
in patients with hypoxia or biventricular failure, is a com-
mon practice in this setting. Rastan and colleagues described 
517 patients receiving ECMO support for PCS. The average 
duration of support was 3.28 days, and 74.1% of patients also 
had an IABP. In this cohort, 63.3% weaned successfully off 
ECMO; however, only 24.8% of all patients made it to hos-
pital discharge. Cumulative survival was 17.6% at six months, 
16.5% at one year, and 13.7% at five years. Unfortunately, these 
patients still have a high in-hospital mortality rate despite 
complete MCS.66
Pitsis et al first described the use of the TandemHeart 
in two patients with postcardiotomy cardiac failure.67 They 
then described a larger cohort of 11 patients who underwent 
TandemHeart support postcardiotomy, with the most com-
mon indication being failure to wean from CPB. The mean 
duration of support was 88 hours, and 72.2% of patients were 
successfully weaned off the pVAD. Survival to discharge was 
54.54%. The major complication was pericardial bleeding.68
The Impella also has been used in the postcardiotomy 
setting. Siegenthaler et al studied 24 patients with PCS 
undergoing Impella implantation (with or without IABP) 
and 198 patients who underwent IABP alone. The use of the 
Impella improved survival over IABP alone in patients with a 
residual cardiac output of 1 L/minute.69 The CentriMag has 
also been demonstrated to be of more benefit when placed in 
patients in the operating room who have failed to wean from 
bypass rather than after decompensation in the intensive 
care unit postoperatively.70 The CentriMag system has also 
been implanted with an ECMO configuration in 14 patients 
with PCS. Seven patients were successfully weaned, and six 
patients were discharged home. All of these patients remained 
on IABP support for at least five days after removal of the 
CentriMag system.71
The Impella 5.0 was studied in the single-arm prospec-
tive feasibility study, RECOVER-1. A total of 16 patients 
underwent implantation for PCS. The primary safety 
 endpoint of death or stroke at 30 days or discharge was noted 
in two patients (94% survived to 30 days, and of those, 93% 
were weaned off MCS). In all, 13 patients recovered their 
native cardiac function and were successfully weaned. The 
last patient required VAD implantation as a BTT. There 
were significant improvements in hemodynamic parameters, 
including mean arterial pressure and cardiac index.72 In a 
larger retrospective review of 47 patients undergoing Impella 
implantation for acute  cardiogenic shock, of those who had 
PCS (68% of patients), the one-year survival was 71.8%.73 The 
Impella 5.0, which crosses the aortic valve, has been success-
Table 5. INTERMACS profile descriptions.61
Profile 1: Critical cardiogenic shock. (“Crash and burn”).
Profile 2: Progressive decline. (“Sliding on inotropes”).
Profile 3: Stable but inotrope dependent. (“Dependent stability”).
Profile 4: Resting symptoms. 
Profile 5: Exertion intolerant.
Profile 6: Exertion limited.
Profile 7: Advanced NYHA III.
Abbreviations: interMaCs, interagency registry for Mechanically assisted 
Circulatory support; nyha, new york heart association.
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fully placed in a patient with PCS after bioprosthetic aortic 
valve replacement.74
Despite major technological advances, PCS remains a 
serious cause of mortality in patients undergoing cardiac sur-
gery, with only about 25% of patients making it to hospital 
discharge.75 Timely initiation of mechanical support, prior to 
complete loss of cardiac function, is imperative. Appropriate 
triage of these patients to centers skilled in the treatment of 
PCS and with the ability of offering advanced HF therapies is 
also of utmost importance in order to improve outcomes.
rV support. Acute RV failure can occur in several set-
tings, including cardiogenic shock and postoperatively after 
heart transplant or surgical LVAD placement. Up to 50% of 
acute inferior wall MIs involve the RV. About 2–3% of heart 
transplant patients, and anywhere from 5 to 44% of patients 
undergoing LVAD, will develop RV failure perioperatively, 
depending on the definition of RV failure (Table 6).76,77 In 
fact, there are several risk models designed to predict post-
operative RV failure.78–80
Preoperatively, RV function can be modified with pul-
monary vasodilators, inotropes, and optimization of RV 
 preload; however, in refractory situations, mechanical support 
may be necessary. The RV differs from the LV in that it usu-
ally recovers more rapidly. Therefore, temporary assist devices 
are preferred. If pulmonary dysfunction and oxygenation are 
issues, ECMO is the best option. Other strategies include the 
use of percutaneous right ventricular assist devices (pRVADs) 
such as the  TandemHeart or CentriMag systems as previously 
described.81
The use of the TandemHeart for RV support was first 
described by Giesler and colleagues in a 57-year-old female with 
RV infarction.82 In a retrospective study of nine patients with 
primary RV failure, Kapur et al described significantly improved 
outcomes after insertion of a pRVAD. Patients underwent 
 TandemHeart placement via right internal  jugular-to-femoral or 
bifemoral cannulation to bypass blood from the RA to the main 
PA. The mean arterial pressure increased from 57 to 75 mmHg, 
right atrial pressure decreased from 22 to 15 mmHg, cardiac 
index increased from 1.5 to 2.3 L/minute/m2, mixed venous 
oxygen saturation increased from 40% to 58%, and RV stroke 
work increased from 3.4 to 9.7 g⋅m/beat. Four patients died 
during hospitalization, and those who survived had a shorter 
time to pRVAD implantation (0.9 days).83 In the more recent, 
larger, multicenter THRIVE Registry, Kapur and colleagues 
found similar outcomes in 40 patients undergoing Tandem-
Heart RV support.84
An RVAD may be temporarily placed in patients with RV 
failure after LVAD implantation. Takagaki et al have described 
successful conversion of a TandemHeart pLVAD to pRVAD 
after implantation of the HeartMate XVE LVAD.85 Similarly, 
Anderson and O’Brien described the use of the Impella LP 
device during HeartMate II implantation.86 The Impella RP 
(specifically designed for the right ventricle) can also be utilized 
for RV support and can deliver up to 4.8 L/minute. The inflow 
is in the inferior vena cava and the outflow in the PA, and the 
axial-flow pump is placed across the tricuspid and pulmonic 
valves in an antegrade fashion. This device is currently under 
investigation. It should be noted that there are no commercially 
available percutaneous devices, specifically for RV support, in 
the US.
Conclusion
Major technological advancements have enabled temporary 
MCS to take on a larger role in the treatment of HF over 
the last decade. Indications have broadened widely from its 
early uses. There are several considerations to keep in mind 
when deciding whether a patient is appropriate for tempo-
rary MCS. One must identify which device would suit him or 
her best, weighing the pros and cons of each method of sup-
port. Most patients requiring temporary support are acutely 
and critically ill, but an effort must be made to make deci-
sions early when possible, ideally prior to a crash and burn 
(ie, INTERMACS 1 profile) situation. There must also be an 
exit strategy prior to insertion of temporary MCS, as its role 
is primarily for the short term as a BTR, permanent support, 
or transplantation.
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